For instance, about 20–30% of HPV(+) HNSCC have mutations in PIK3CA [53]; detecting a PIK3CA mutation in plasma ctDNA alongside HPV16 might indicate a high tumor fraction and possibly identify a targetable pathway (PI3K inhibitors). This evidence concerns the gene PIK3CA and neoplasm.